Sep 11, 2023 / 06:55PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Okay. Great. I think we're going to get started. Thanks for joining us this afternoon. I'm Terence Flynn, the U.S. biopharma analyst at Morgan Stanley. Very pleased to be hosting Eli Lilly. We have Dan Skovronsky, who is the company's CFO and SMO.
Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com\researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Well, Dan, thanks so much for joining us today. I know it's been a busy time at the company. So I appreciate you being able to step away here and spend some time with us at our conference.
Questions and Answers:
Terence C. Flynn - Morgan Stanley, Research Division - Equity AnalystI guess just the big picture one I had to start it off is just it's been a tremendously productive time for the company, as you've highlighted over the last year or so. So just as you think
Trustpilot
